GLP1_NEW
Exenatide and rosiglitazone 10 to 4 µg injection twice daily
EXENROSI_SC_10-4UG_BID
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.21 (-1.77 to -0.64) | 0.77 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -0.06 (-2.37 to 2.11) | 0.44 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 1.90 (0.55 to 6.45) | 0.39 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.19 (0.27 to 5.35) | 0.43 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 3.71 (1.71 to 7.93) | 0.37 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 2.47 (0.87 to 7.05) | 0.52 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 4.07 (1.21 to 16.31) | 0.18 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 2.43 (0.40 to 17.04) | 0.37 |